known pharmacokinetic drug-drug interactions. In recent years, several reports have shown an association between PPI co-administration and the delayed elimination of MTX (Bezabeh, Mackey, Kluetz, Jappar, & Korvick, 2012; Joerger et al., 2006; Santucci, Levêque, Lescoute, Kemmel, & Herbrecht, 2010; Suzuki et al., 2009) . Moreover, two case reports described no evidence of delayed MTX elimination when a H 2 RA, such as ranitidine, was substituted for a PPI (Bauters, Verlooy, Robays, & Laureys, 2008; Beorlegui, Aldaz, Ortega, Aquerreta, Sierrasesumega, & Giraldez, 2000) . However, the mechanism of this interaction is not clear, and there is no evidence that suggests a reduced risk for patients treated with H 2 RAs in conjunction with HD-MTX.
Methotrexate is predominantly excreted renally, and cytochrome P450 (CYP) enzymes are not involved in MTX metabolism. Although several transporters have been previously reported to be involved in the renal elimination of MTX, organic anion transporter 3 (OAT3) has been shown to be a high-affinity transporter for MTX uptake into renal proximal tubule cells (Breedveld et al., 2004; Chen et al., 2002; Takeda et al., 2002; Uwai et al., 2004) . Human OAT3 is localized to the basolateral membrane of proximal tubular epithelial cells and plays an important role in renal drug elimination from the blood to proximal tubules (Cha et al., 2001; Rizwan & Burckhardt, 2007) .
Several drugs, such as ketoprofen and probenecid, are known to inhibit the elimination of MTX (Aherne et al., 1978; Thyss, Milano, Kubar, Namer, & Schneider, 1986) . The mechanism underlying these interactions partially relies on the inhibition of the renal elimination of MTX via OAT3 (Nozaki et al., 2007; Takeda et al., 2002) . A recent study reported that PPI, such as lansoprazole, inhibited hOAT3-mediated transport of pemetrexed, which has a chemical structure similar to MTX, in a competitive manner (Ikemura et al., 2016) . However, there is little information regarding the association between the inhibitory effect of antisecretory drugs on OAT3-mediated MTX transport and delayed elimination of MTX.
In the present study, the impact of antisecretory drugs on plasma MTX elimination was retrospectively analysed in hospitalized cancer patients who received HD-MTX therapy. The study also assessed the inhibitory effects of four PPIs (esomeprazole, lansoprazole, omeprazole and rabeprazole) or famotidine on OAT3-mediated transport of MTX in hOAT3-expressing cultured cells.
| MATERIALS AND METHODS

| Patients and data collection
A retrospective study was conducted in hospitalized patients who received treatment with HD-MTX at Hokkaido University Hospital (Sapporo, Japan) between April 2010 and March 2014. The study included 73 cycles of HD-MTX therapy involving 43 patients. All the patients received intravenous fluids for hydration and alkalization of urine using sodium bicarbonate to maintain urine pH >7 during treatment. Patients who met any of the following criteria were excluded from the study: (1) below 18 years of age; (2) used NSAIDs during HD-MTX treatment; (3) had no monitored plasma methotrexate concentration at 48 h and/or 72 h. Patient information and data were extracted from electronic medical records kept in a central database in our hospital. The present study was approved by the Institutional Review Board of the Hokkaido University Hospital and also was conducted in accordance with the Declaration of Helsinki.
Electronic medical records of patients were followed until plasma MTX levels fell below ≤0. in the G418 resistant clones was determined by RT-PCR and functional analyses (Supplemental Figure 1 ).
| Uptake study in hOAT3-expressing cells
The hOAT3 to measure the radioactivity. To quantify the 6-CF accumulation, the cells were dissolved in 0.5 ml 0.5 N NaOH and the 6-CF accumulation was determined in a fluorescence spectrophotometer (Hitachi, Tokyo, Japan) at 490/520 nm (excitation/emission). The protein concentration was determined using a Pierce ® BCA protein assay kit (Thermo Scientific, Waltham, MA, USA), in accordance with the manufacturer's instructions. All uptake values were corrected for protein content.
| Statistical analysis
Statistical assessment of patient data was analysed using IBM SPSS Statistics software, version 23, (SPSS Inc., Chicago, IL, USA). The differences in baseline clinical characteristics were compared between patients receiving PPI and not receiving PPI by the Fisher's exact probability test or the Mann-Whitney U-test. Differences in plasma MTX levels between the two groups were assessed using the Mann-Whitney U-test.
Data from the in vitro experiments are expressed as the mean ± standard deviation (SD). To determine the IC 50 value of each inhibitor for the inhibition of MTX uptake, the data points were analysed using nonlinear regression analysis fitting a 4-parameter logistic equation using SigmaPlot 12.5 (Systat Software, Inc.; San Jose, CA, USA).
3 | RESULTS
| Patient characteristics
One hundred and six cycles of HD-MTX were initially identified. However, 33 cycles were excluded for the following reasons: one was younger than 18, 13 involved co-administration of NSAIDs and 19 had incomplete medical data. Thus, 43 patients receiving 73 cycles of HD-MTX were included in this analysis. Retrospectively, the 73 cycles of HD-MTX were categorized into two groups: with PPI (n = 26; esomeprazole (n = 7), lansoprazole (n = 3), omeprazole (n = 4) and rabeprazole (n = 12)) and without PPI (n = 47). The baseline patient characteristics are shown in Table 1 . Baseline characteristics were well balanced among the two groups, except for sex, MTX dose and MTX infusion time. Male sex and long infusion time were significantly more frequent in the group receiving PPI than in the group not receiving PPI.
All patients in the group not receiving PPI were co-administered famotidine, a commonly used H 2 RA.
| Comparison of the plasma MTX levels
Patients who received a PPI had significantly higher MTX levels at 48 h 
| DISCUSSION
A number of retrospective studies have suggested an association between the co-administration of PPIs and delayed elimination of MTX, although the mechanism for this interaction is not well understood (Bezabeh et al., 2012) . The present study was conducted to provide important information for safe and appropriate chemotherapy with HD-MTX during co-administration with gastric antisecretory drugs. To achieve this goal the impact of PPIs on plasma MTX elimination was retrospectively analysed, and the drug interaction between MTX and antisecretory drugs, including PPIs, examined using a cell system that stably expresses the human OAT3.
In a retrospective study, the 73 cycles of HD-MTX were categorized into two groups, those that received PPIs and those that did not receive PPIs, and a statistically significant difference was found in the plasma MTX levels between the groups (Table 1, Figure 1 ).
Although the patients who received a PPI had significantly higher MTX levels at each measured time point, the patients who received a PPI were also more likely to have a long MTX infusion time compared with patients who did not receive a PPI. This finding is consistent with a previous report that showed patients receiving PPIs had significantly longer infusion times along with higher MTX levels (Reeves, Moore, Bascom, & Rensing, 2014 patients who concomitantly received famotidine (and did not receive a PPI) had lower MTX levels supports previous case reports that no delayed MTX elimination was found when a H 2 RA was substituted for a PPI (Bauters et al., 2008; Beorlegui et al., 2000) . Therefore, substitution of H 2 RA in place of PPI, or stopping PPI a few days before HD-MTX therapy, would seem prudent until further data have been obtained. However, similar to the other studies describing a possible interaction between MTX and PPIs, the present study is limited by its retrospective nature, and was analysed per cycle of treatment with HD-MTX, but not per patient (Bezabeh et al., 2012; Santucci et al., 2010; Suzuki et al., 2009) . Future studies should include a large-scale prospective study to adjust for the number of HD-MTX cycles per patient and other potential confounders, such as sex and MTX infusion time.
Multiple renal transporters are involved in MTX pharmacokinetics.
In the apical membrane of proximal tubular epithelial cells, breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) are considered to be responsible for the active secretion of MTX into the urine. Breedveld et al. reported that pantoprazole inhibited MTX transport via inhibition of BCRP but not MRP2 (Breedveld et al., 2004) . Another study has shown that four PPIs (omeprazole, lansoprazole, rabeprazole and pantoprazole) inhibited BCRP-mediated transport of MTX (Suzuki et al., 2009 ). The reported IC 50 values of these PPIs were much higher than unbound plasma levels of PPIs in the therapeutic range. Therefore, the drug-drug interaction between MTX and PPIs is unlikely to be the result of the inhibitory effect of PPIs on renal apical membrane-mediated MTX transport. Different OATs (OAT1 and OAT3) localize to the basolateral membranes of the renal proximal tubule and have been shown to transport MTX (Cha et al., 2001; Hosoyamada, Sekine, Kanai, & Endou, 1999; Uwai et al., 2004) . The affinity of MTX for hOAT3 (K m : 17 μM) obtained from previously published data was much higher than that for hOAT1 (K m : 724 μM) . Nozaki et al. demonstrated that MTX uptake by human kidney slices was saturable with K m values of 44.6 ± 23.4 μM. Considering that the K m value determined in that study is similar to the value for hOAT3, it is likely that hOAT3 contributes more significantly to renal MTX clearance and affects the pharmacokinetics of MTX (Nozaki et al., 2007) . Chioukh et al. reported that three PPIs (omeprazole, lansoprazole and pantoprazole) can significantly inhibit hOAT3-mediated uptake of MTX (Chioukh et al., 2014) .
However, little is known about the effect of famotidine and other PPIs on hOAT3-mediated MTX transport. Based on these findings, we hypothesized that the underlying mechanisms whereby PPIs, but not famotidine, may affect the elimination of plasma MTX is partially dependent on the inhibition of the renal elimination via hOAT3. The inhibitory effects of these drugs was first examined on the hOAT3-mediated uptake of 6-CF; among the PPIs tested, lansoprazole exhibited the most potent inhibitory effect (Supplemental Figure 2) . Additionally, each PPI tested also inhibited the hOAT3-mediated uptake of MTX in a concentration-dependent manner (Figure 2) . The observed IC 50 values of each PPI for the inhibition of MTX uptake were in the micromolar range (1.2, 0.40, 5.5 and 4.8 μM for esomeprazole, lansoprazole, omeprazole and rabeprazole, respectively). The IC 50 value of lansoprazole for the inhibition of hOAT3-mediated MTX uptake is nearly consistent with that of the previous reports (Chioukh et al., 2014) . In contrast to PPIs, famotidine showed little inhibitory effect on the hOAT3-mediated uptake of either MTX or 6-CF. Although famotidine is a known substrate of hOAT3 (K m : 124 μM), the uptake of E3S, a substrate of hOAT3, is not inhibited by famotidine at 10 μM (Motohashi, Uwai, Hiramoto, Okuda, & Inui, 2004; Tahara et al., 2005) . After a single oral dose of 40 mg, the maximum plasma concentration for famotidine is much less than 1 μM (Lin et al., 1987) . These results suggest that a relevant interaction of hOAT3 with famotidine under a clinically used concentration is unlikely. According to the recommendation of the International Transporter Consortium (Giacomini et al., 2010) , if the ratio of unbound C max to IC 50 value (C max,u / IC 50 ) is greater than or equal to 0.1 then a clinical drug-drug interaction study should be performed. As shown in Supplemental Table 1 (Andersson, Hassan-Alin, Hasselgren, Rohss & Weidolf, 2001; Freston, Chiu, Mulford, & Ballard, 2003; Lind et al., 2000; McCallum et al., 2014; Tahara et al., 2005; Yasuda et al., 1994) , the ratio of unbound C max to IC 50 value of lansoprazole was 0.33, whereas those of the other PPIs were lower than 0.1. These findings suggest that co-administration of PPIs, especially lansoprazole, and MTX could lead to a clinical drug interaction.
To the best of our knowledge, there are no reports correlating the inhibitory effect of antisecretory drugs on hOAT3-mediated MTX transport with variations in plasma disposition of MTX in humans. To confirm the significant effects of PPI, the incidence of delayed plasma MTX elimination was compared between HD-MTX therapy with (n = 26) and without (n = 47) PPI co-administration. Delayed elimination of MTX was significantly more frequent in the PPI group than in the group not receiving PPIs (53.8% vs. 10.6%). The frequency of delayed MTX elimination in patients administered esomeprazole, lansoprazole, omeprazole or rabeprazole was 71.4% (5/7), 100% (3/3), 25.0% (1/4) and 41.7% (5/12), respectively. Additionally, all patients in the group not receiving PPI were co-administered famotidine. Considering the rank order of inhibitory potency of gastric antisecretory drugs for hOAT3-mediated MTX uptake, the differential inhibitory effects of these drugs on hOAT3-mediated MTX transport in vitro may explain the frequency of delayed MTX excretion. Interestingly, our retrospective data revealed that delayed elimination of MTX was observed in every patient receiving lansoprazole. Lansoprazole exhibited the most potent inhibitory effect against hOAT3-mediated MTX uptake in vitro, and this interaction may be, at least in part, a contributing factor to delay the elimination of MTX. However, delayed elimination was similarly observed in patients receiving the other PPI or famotidine, and other factors are also likely to contribute to the delayed elimination of MTX. PPIs are metabolized by multiple CYP enzymes, including CYP2C19. Approximately 20% of the Japanese population has been identified as poor metabolizers of CYP2C19 (Kubota, Chiba, & Ishizaki, 1996) . A previous report described the C max of esomeprazole in CYP2C19-poor (7.8 μM) and -extensive (5.4 μM) metabolizers, after a single oral dose of 40 mg (Andersson, HassanAlin, Hasselgren, Röhss, & Weidolf, 2001) . In poor metabolizers of CYP2C19, the ratio of unbound C max to esomeprazole IC 50 values, especially at the 40 mg dose, was greater than 0.1. Therefore, the CYP2C19 metabolizer status, which provides higher plasma levels of PPIs, may significantly influence the magnitude of the PPI-MTX interaction. Another genetic risk factor for delayed MTX elimination may involve polymorphisms in the organic anion-transporting polypeptide 1B1 (OATP1B1, encoded by the SLCO1B1 gene). OATP1B1 is a human hepatic uptake transporter localized on the sinusoidal membrane of hepatocytes, where it mediates the uptake of a wide variety of drugs from blood into liver (Abe et al., 1999; König, Cui, Nies, & Keppler, 2000) . OATP1B1 is able to transport MTX in vitro, and it mediates the uptake of MTX into the liver (Abe et al., 2001; van de Steeg et al., 2009) . Several reports have shown that single-nucleotide polymorphisms (SNPs) in SLCO1B1 associated with decreased transport activity were linked to decreased MTX clearance in patients treated with HD-MTX, suggesting the importance of hepatic uptake pathways in MTX pharmacokinetics (Lopez-Lopez et al., 2011; Tirona, Leake, Merino, & Kim, 2001; Treviño et al., 2009) . Therefore, the difference in genetic background, particularly involving CYP2C19 and OATP1B1 activity, may partially explain the discrepancy in the association between co-administration of PPIs and delayed MTX excretion. Additionally, it may be possible that OATP1B1 is involved in the PPI-MTX drug interaction, although the inhibitory effect of PPIs on OATP1B1-mediated MTX transport remains to be elucidated.
OAT1 can also transport MTX but with a much lower affinity than OAT3, as mentioned above. Zarychanski et al. reported that the peak serum levels of MTX were higher than 100 μM following high-dose infusional therapy (Zarychanski et al., 2006) . Our preliminary data show slight inhibitory effects of PPIs on the uptake of 6-CF via hOAT1 (data not shown). These findings imply that inhibitory effects of PPIs on both hOAT3 and hOAT1 may also be attributable to PPI-MTX drug interaction. However, the contribution of their transporters to this interaction remains unclear and requires further investigation. Other transporters have been identified in the kidney. OATP4C1 is also localized at the basolateral membranes of proximal tubule cells, and has been shown to transport MTX (Mikkaichi et al., 2004) . A recent study found that lansoprazole (100 μM) and rabeprazole (100 μM) caused no inhibition of OATP4C1-mediated transport of triiodothyronine (Sato, Mishima, Mano, Abe, & Yamaguchi, 2017) . These findings suggest that OATP4C1 is not responsible for the PPI-MTX interaction. Studies measuring the contribution of other transporters to PPI-MTX drug interaction, as well as the impact of genetic variants on drug metabolism and transport, are required to clarify the clinical significance of PPI-MTX drug interaction.
| CONCLUSION
The study found that patients who received a PPI had significantly higher MTX levels following HD-MTX treatment than patients who received famotidine. Additionally, the in vitro data indicate that PPIs, but not famotidine, inhibit hOAT3-mediated MTX transport under clinical concentrations, which likely explains, at least in part, the drug-drug interactions observed between MTX and PPIs.
